GBIO News and Press, Generation Bio Co. From 06/02/22

CAMBRIDGE, Mass., June 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate i...

Generation Bio press release (NASDAQ:GBIO): Q1 GAAP EPS of -$0.61 misses by $0.08. Cash and cash equivalents of $337M will fund operating plan into 2024. The net decrease in cash and cash equivalents during the first quarter of 2022 includes cash outflows for seasonal and one-time expenditure...

Company continues to optimize cell-targeted lipid nanoparticle (ctLNP) delivery system for nonviral genetic medicine applications in liver, retina and vaccines Cash balance of $337.0M expected to fund operations into 2024 CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- ...

Gainers: Spruce Biosciences (SPRB) +7%. ThredUp  (TDUP) +7%. Cellectis  (CLLS) +6%. Revolution Medicines (RVMD) +5%. Ocular Therapeutix (OCUL) +5%. Losers: Trean Insurance Group (TIG) -7%. Lyell Immunopharma (LYEL) -6%. Vivid Seats  (SEAT) -6%. Y-mAbs Therapeutic...

Shares of Generation Bio Co. (NASDAQ:GBIO) traded at a new 52-week high today of $55.56. Approximately 7.3 million shares have changed hands today, as compared to an average 30-day volume of 490,000 shares. Generation Bio Co. (NASDAQ:GBIO) defies analysts with a current price ($8.95) 0.5...

CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate ...

CAMBRIDGE, Mass., March 02, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co. (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, announced that Geoff McDonough, M.D., president and chief executive officer, will participate ...

Generation Bio press release (NASDAQ:GBIO): Q4 GAAP EPS of -$0.54 beats by $0.03. Cash and cash equivalents were $375.1M as of December 31, 2021 For further details see: Generation Bio GAAP EPS of -$0.54 beats by $0.03

CAMBRIDGE, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Generation Bio Co . (Nasdaq: GBIO), a biotechnology company innovating genetic medicines for people living with rare and prevalent diseases, outlined its strategic priorities for 2022 and reported fourth quarter and full year 2021 fina...

Generation Bio (NASDAQ:GBIO) announced Thursday the promotion of Antoinette Paone to chief operating officer.  Paone has served as senior vice president and head of regulatory affairs and quality at Generation Bio since 2018. Prior to Generation Bio, Paone p...